Breakthrough Study: Ketamine Shows 70% Response Rate in Treatment-Resistant Depression

Key Findings

A groundbreaking multi-center study published this month in JAMA Psychiatry has demonstrated that intravenous ketamine therapy achieves a remarkable 70% response rate in patients with treatment-resistant depression (TRD). This landmark research, conducted across 15 clinical sites with over 500 participants, provides the strongest evidence yet for ketamine as a viable treatment option for those who have not responded to traditional antidepressants.

#

Study Design and Methodology

The randomized, double-blind, placebo-controlled trial enrolled 512 adults aged 18-65 who had failed to respond to at least two adequate trials of antidepressant medications. Participants received either:

- Active treatment group: Six IV ketamine infusions (0.5 mg/kg over 40 minutes) over two weeks
- Control group: Saline placebo infusions with identical administration protocols

Primary outcomes were measured using the Montgomery-Asberg Depression Rating Scale (MADRS) at two weeks, with secondary endpoints including remission rates, sustained response at 12 weeks, and safety assessments.

Results That Change Everything

The findings exceeded expectations across all measured parameters:

#

Primary Outcomes
- 70% response rate in the ketamine group vs. 23% in placebo
- 45% remission rate achieved with ketamine treatment
- Rapid onset: Mean time to initial response was 4.2 days

#

Secondary Outcomes
- Sustained response maintained in 58% of responders at 12-week follow-up
- Significant improvements in anxiety symptoms (p < 0.001)
- Quality of life measures improved by 40% on average

"These results represent a paradigm shift in how we approach treatment-resistant depression. For patients who have struggled for years without relief, ketamine offers genuine hope."
>

— Dr. Maria Santos, Lead Investigator, Stanford University

Safety Profile

The study confirmed ketamine's favorable safety profile when administered in clinical settings:

- Dissociative symptoms: Mild and transient, resolving within 2 hours
- Blood pressure elevations: Modest increases returned to baseline within 1 hour
- No serious adverse events attributable to treatment
- Cognitive assessments: No impairment at 24 hours post-infusion

#

Most Common Side Effects
1. Dizziness (38%)
2. Nausea (27%)
3. Headache (21%)
4. Perceptual disturbances (19%)

Implications for Clinical Practice

These findings have immediate implications for ketamine therapy providers:

#

Treatment Protocols
The study validated the commonly used six-infusion induction protocol, providing evidence-based support for current clinical practices. Key protocol elements included:

- 0.5 mg/kg IV ketamine administered over 40 minutes
- Three sessions per week for two weeks
- Monitoring for at least 2 hours post-infusion
- Blood pressure checks every 15 minutes during infusion

#

Patient Selection
The research identified factors associated with better outcomes:

- Shorter duration of current depressive episode
- Absence of personality disorders
- No active substance use disorder
- Adequate social support systems

What This Means for the Field

This study represents the largest and most rigorous trial of ketamine for depression to date. Its findings support ketamine's position as a legitimate treatment option for TRD and may influence:

1. Insurance coverage decisions as evidence mounts for efficacy
2. Clinical guidelines from major psychiatric organizations
3. FDA considerations for expanded indications
4. Provider training requirements and certification standards

Next Steps

The research team has announced plans for follow-up studies examining:

- Longer-term maintenance protocols
- Combination treatments with psychotherapy
- Biomarkers predicting treatment response
- Optimal dosing strategies for different patient populations

For ketamine therapy providers, this study reinforces the importance of adherence to evidence-based protocols while highlighting the tremendous potential of this treatment modality.

---

The full study, "Efficacy and Safety of Intravenous Ketamine for Treatment-Resistant Depression: A Randomized Clinical Trial," is available in the January 2026 issue of JAMA Psychiatry.